200 related articles for article (PubMed ID: 32298138)
21. Pancreatic Solid Pseudopapillary Neoplasm: Key Pathologic and Genetic Features.
La Rosa S; Bongiovanni M
Arch Pathol Lab Med; 2020 Jul; 144(7):829-837. PubMed ID: 31958381
[TBL] [Abstract][Full Text] [Related]
22. Survival comparison between primary hepatic neuroendocrine neoplasms and primary pancreatic neuroendocrine neoplasms and the analysis on prognosis-related factors.
Li MX; Li QY; Xiao M; Wan DL; Chen XH; Zhou L; Xie HY; Zheng SS
Hepatobiliary Pancreat Dis Int; 2019 Dec; 18(6):538-545. PubMed ID: 30981633
[TBL] [Abstract][Full Text] [Related]
23. Pathology and Surgical Treatment of High-Grade Pancreatic Neuroendocrine Carcinoma: an Evolving Landscape.
Haugvik SP; Kaemmerer D; Gaujoux S; Labori KJ; Verbeke CS; Gladhaug IP
Curr Oncol Rep; 2016 May; 18(5):28. PubMed ID: 26984415
[TBL] [Abstract][Full Text] [Related]
24. Identification and characterization of poorly differentiated invasive carcinomas in a mouse model of pancreatic neuroendocrine tumorigenesis.
Hunter KE; Quick ML; Sadanandam A; Hanahan D; Joyce JA
PLoS One; 2013; 8(5):e64472. PubMed ID: 23691228
[TBL] [Abstract][Full Text] [Related]
25. Pancreatic Neoplasms With Acinar Differentiation: A Review of Pathologic and Molecular Features.
Thompson ED; Wood LD
Arch Pathol Lab Med; 2020 Jul; 144(7):808-815. PubMed ID: 31869246
[TBL] [Abstract][Full Text] [Related]
26. Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future.
Ohmoto A; Rokutan H; Yachida S
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28098761
[TBL] [Abstract][Full Text] [Related]
27. The molecular biology of pancreatic neuroendocrine neoplasms: Challenges and translational opportunities.
Young K; Starling N; Sadanandam A
Semin Cancer Biol; 2020 Apr; 61():132-138. PubMed ID: 31577961
[TBL] [Abstract][Full Text] [Related]
28. Personalized treatment approach to gastroenteropancreatic neuroendocrine tumors: a medical oncologist's perspective.
Paul D; Ostwal V; Bose S; Basu S; Gupta S
Eur J Gastroenterol Hepatol; 2016 Sep; 28(9):985-90. PubMed ID: 27257869
[TBL] [Abstract][Full Text] [Related]
29. Well-differentiated pancreatic neuroendocrine tumours (PanNETs) and poorly differentiated pancreatic neuroendocrine carcinomas (PanNECs): concepts, issues and a practical diagnostic approach to high-grade (G3) cases.
Singhi AD; Klimstra DS
Histopathology; 2018 Jan; 72(1):168-177. PubMed ID: 29239037
[TBL] [Abstract][Full Text] [Related]
30. Genetics and molecular pathology of neuroendocrine gastrointestinal and pancreatic tumors (gastroenteropancreatic neuroendocrine tumors).
Oberg K
Curr Opin Endocrinol Diabetes Obes; 2009 Feb; 16(1):72-8. PubMed ID: 19115524
[TBL] [Abstract][Full Text] [Related]
31. Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
Janson ET; Sorbye H; Welin S; Federspiel B; Grønbæk H; Hellman P; Ladekarl M; Langer SW; Mortensen J; Schalin-Jäntti C; Sundin A; Sundlöv A; Thiis-Evensen E; Knigge U
Acta Oncol; 2014 Oct; 53(10):1284-97. PubMed ID: 25140861
[TBL] [Abstract][Full Text] [Related]
32. Endocrine tumours of the gastrointestinal tract. Introduction: definition, historical aspects, classification, staging, prognosis and therapeutic options.
Arnold R
Best Pract Res Clin Gastroenterol; 2005 Aug; 19(4):491-505. PubMed ID: 16183523
[TBL] [Abstract][Full Text] [Related]
33. Colorectal poorly differentiated neuroendocrine carcinomas frequently exhibit BRAF mutations and are associated with poor overall survival.
Olevian DC; Nikiforova MN; Chiosea S; Sun W; Bahary N; Kuan SF; Pai RK
Hum Pathol; 2016 Mar; 49():124-34. PubMed ID: 26826419
[TBL] [Abstract][Full Text] [Related]
34. Assessment of cytologic differentiation in high-grade pancreatic neuroendocrine neoplasms: A multi-institutional study.
Sigel CS; Krauss Silva VW; Reid MD; Chhieng D; Basturk O; Sigel KM; Daniel TD; Klimstra DS; Tang LH
Cancer Cytopathol; 2018 Jan; 126(1):44-53. PubMed ID: 29044913
[TBL] [Abstract][Full Text] [Related]
35. Site-Specific Genomic Alterations in a Well-Differentiated Pancreatic Neuroendocrine Tumor With High-Grade Progression.
Martin DR; LaBauve E; Pomo JM; Chiu VK; Hanson JA; Gullapalli RR
Pancreas; 2018 Apr; 47(4):502-510. PubMed ID: 29521944
[TBL] [Abstract][Full Text] [Related]
36. Well-differentiated pancreatic neuroendocrine carcinoma in tuberous sclerosis--case report and review of the literature.
Arva NC; Pappas JG; Bhatla T; Raetz EA; Macari M; Ginsburg HB; Hajdu CH
Am J Surg Pathol; 2012 Jan; 36(1):149-53. PubMed ID: 22173120
[TBL] [Abstract][Full Text] [Related]
37. The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond.
Sorbye H; Baudin E; Perren A
Endocrinol Metab Clin North Am; 2018 Sep; 47(3):683-698. PubMed ID: 30098724
[TBL] [Abstract][Full Text] [Related]
38. Insulinoma-associated protein 1 (INSM1) is a useful marker for pancreatic neuroendocrine tumor.
Tanigawa M; Nakayama M; Taira T; Hattori S; Mihara Y; Kondo R; Kusano H; Nakamura K; Abe Y; Ishida Y; Okabe Y; Hisaka T; Okuda K; Fujino K; Ito T; Kawahara A; Naito Y; Yamaguchi R; Akiba J; Akagi Y; Yano H
Med Mol Morphol; 2018 Mar; 51(1):32-40. PubMed ID: 28849340
[TBL] [Abstract][Full Text] [Related]
39. [Classification of pancreatic neuroendocrine tumours: Changes made in the 2017 WHO classification of tumours of endocrine organs and perspectives for the future].
Scoazec JY; Couvelard A;
Ann Pathol; 2017 Dec; 37(6):444-456. PubMed ID: 29169836
[TBL] [Abstract][Full Text] [Related]
40. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology.
Crippa S; Partelli S; Belfiori G; Palucci M; Muffatti F; Adamenko O; Cardinali L; Doglioni C; Zamboni G; Falconi M
World J Gastroenterol; 2016 Dec; 22(45):9944-9953. PubMed ID: 28018101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
